These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16304750)

  • 1. Global medicine does not make for global courts.
    Herling DJ; Brenner LM
    Food Drug Law J; 2005; 60(3):453-7. PubMed ID: 16304750
    [No Abstract]   [Full Text] [Related]  

  • 2. The International Conference on Harmonization common technical document--global submission format?
    Molzon JA
    Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749
    [No Abstract]   [Full Text] [Related]  

  • 3. US courts narrow patent exemptions.
    Fox JL
    Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
    [No Abstract]   [Full Text] [Related]  

  • 4. US bill to shield drug companies from product liability.
    Lenzer J
    BMJ; 2005 Jan; 330(7482):62. PubMed ID: 15637367
    [No Abstract]   [Full Text] [Related]  

  • 5. The new Restatement (Third) of Torts--shelter from the product liability storm for pharmaceutical companies and medical device manufacturers?
    Wagner MJ; Peterson LL
    Food Drug Law J; 1998; 53(2):225-42. PubMed ID: 10346683
    [No Abstract]   [Full Text] [Related]  

  • 6. The "tone at the top": can it mitigate C-suite personal liability?
    Page GV; Waring MA; Kaiser GR; Cornish K
    Food Drug Law J; 2008; 63(3):723-34. PubMed ID: 19031671
    [No Abstract]   [Full Text] [Related]  

  • 7. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 8. Integra v. Merck: a mixed bag for research tool patents.
    Raubicheck C; White BS; Kowalski TJ; Brown DG; Leahy A; Fekete P
    Nat Biotechnol; 2003 Sep; 21(9):1099-101. PubMed ID: 12949571
    [No Abstract]   [Full Text] [Related]  

  • 9. Market share liability for pharmaceuticals. The distinction between DES and DPT.
    Fern FH; McHugh LS
    J Leg Med; 1990 Dec; 11(4):391-426. PubMed ID: 2292665
    [No Abstract]   [Full Text] [Related]  

  • 10. Global harmonization is not all that global: divergent approaches in drug safety.
    Castle GH; Kelly B
    Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug regulation 2056.
    Bezold C; Peck J
    Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
    [No Abstract]   [Full Text] [Related]  

  • 12. Revisiting Factor VIII cases: is it time for an agency adjudication system?
    Su YC
    Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390
    [No Abstract]   [Full Text] [Related]  

  • 13. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 14. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 15. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rights, patents, markets and the global AIDS pandemic.
    Gathii JT
    Fla J Int Law; 2002; 14(2):261-352. PubMed ID: 16526139
    [No Abstract]   [Full Text] [Related]  

  • 17. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 18. Wyeth Pharmaceutical's perspective on vaccine production.
    Stiles GL
    Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
    [No Abstract]   [Full Text] [Related]  

  • 19. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical Protections in U.S. Trade Deals - What Do Americans Get in Return?
    Bollyky T; Kesselheim AS
    N Engl J Med; 2019 May; 380(21):1993-1995. PubMed ID: 31042823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.